VC-LC-0729 is a structurally optimized ionizable lipid for LNPs, combining a dimethylaminoethyl headgroup for pH-sensitive charge modulation with a disulfide-thioether hybrid backbone to improve biodegradability. The lipid includes unsaturated C18 alkenyl chains (e.g., linoleyl) to enhance membrane fluidity and cellular uptake. In vitro studies reveal that VC-LC-0729 enables >90% mRNA encapsulation efficiency and sustains protein expression in hepatocytes and dendritic cells. In vivo evaluations in murine models show rapid antigen production post-administration, outperforming commercial lipids like ALC-0315 in both potency and duration of expression. The ester and thioether linkages facilitate enzymatic degradation, reducing systemic toxicity. VC-LC-0729-based LNPs also demonstrate excellent stability at -20°C for over 6 months, making them suitable for global distribution. These attributes position VC-LC-0729 as a promising candidate for mRNA vaccines and gene therapies requiring high transfection efficiency and low immunogenicity.
Cat.No
DC60846
Name
Moderna VC-LC-0729
Chemical Properties
CAS
Formula
C43H85O4N3S
MW
740.23
Storage
2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
References
Return Policy
If you are in any way unsatisfied with your purchase, you may return any item(s) within 365 days of its original purchase date.
Please provide your Order Number in the email. We strive to reply to all email inquiries within one business day.
